GlycoNet researchers studying complex enzymes gain insight into how some pathogens could potentially be targeted without antibiotics.
SARS-CoV-2 uses sugars to invade human cells, new study shows
Understanding the process could help scientists look out for new, more infectious variants, say GlycoNet researchers.
New anti-diabetic treatment approved for human trials
A natural compound that slows the breakdown of starch could be used to develop a more pleasant treatment for managing Type 2 diabetes.
Announcing the new GlycoNet Trainee Association Executive Committee
The committee will support GlycoNet trainees in advancing their skills and knowledge through professional development activities.
GlycoNet Mini-Symposium gathered trainees from coast to coast
The event brought together trainees from Western, Central, and East Coast regions to network and exchange knowledge.
GlycoNet receives government funding to encourage confidence in vaccines across the country
The grant will help deliver reliable vaccine information to help Canadians make evidence-based decisions on vaccines.
GlycoNet joins national industry association to drive economic growth in the biotechnology sector
As a member of BIOTECanada’s network, GlycoNet aims to mobilize glycomics research into tangible and sustainable innovation for Canadians.
Innovative coating for blood vessels reduces rejection of transplanted organs
Knowledge in the sugars that coat blood vessels helps researchers find a way to reduce organ rejection.
Solving blood supply shortage with glycomics
GlycoNet Investigators study the sugars on red blood cells to find ways to make universal donor blood
GlycoNet start-up listed as top 10 therapeutics start-ups and companies in Edmonton
48Hour Discovery shows exceptional innovation, growth, management, and societal impact, according to BestStartup.
English 
French